Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsDowngradesPrice TargetHot
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.